Noise Over DCBs Clouds An Otherwise Okay Quarter At Bard
Stephen Simpson, CFA
Stephen Simpson, CFA
Fri, Jul. 1, 7:03 AM
- June monthly performance was: +2.86%
- 52-week performance vs. the S&P 500 is: +7%
- $0.25 in dividends were paid in June
- Top 10 Holdings as of 5/31/2016: S&P Global Inc (SPGI): 2.15464%, Archer-Daniels Midland Co (ADM): 2.15039%, Cincinnati Financial Corp (CINF): 2.13109%, McCormick & Co Inc Non-Voting (MKC): 2.10728%, C.R. Bard Inc (BCR): 2.10554%, Cintas Corp (CTAS): 2.10524%, Leggett & Platt Inc (LEG): 2.10068%, Lowe's Companies Inc (LOW): 2.09886%, Brown-Forman Corp Class B (BF.B): 2.09499%, Pentair PLC (PNR): 2.09495%
Mon, Jun. 27, 11:16 AM
- The outperformance of low-P/E stocks that marked H1 is behind us, says RBC's Jonathan Golub, and it's time for the "Stable Growers" to re-asset leadership. He cautions about putting money to work too quickly though, noting the pullback so far has been limited.
- His list of Stable Growers (page 1, page 2): CHD, CL, CVS, K, MO, PEP, PG, PM, BCR, BDX, DGX, DVA, HSIC, JNJ, LH, MDT, SYK, TMO, UNH, ZBH, AFL, AON, MMC, TMK, CTAS, DHR, HON, ITW, LMT, MMM, NLSN, RSG, RTN, UPS, VRSK, WM, XYL, CMCSA, MCD, OMC, ADP, APH, EMC, MA, T, VZ, ECL, PX
Wed, Jun. 8, 5:16 PM
Wed, Jun. 8, 4:41 PM
Thu, Jun. 2, 7:46 AM
- May monthly performance was: +0.76%
- 52-week performance vs. the S&P 500 is: +7%
- No dividends were paid in May
- Top 10 Holdings as of 4/30/2016: Consolidated Edison Inc (ED): 2.09%, Leggett & Platt Inc (LEG): 2.07%, S&P Global Inc (SPGI): 2.07%, Brown-Forman Corp Class B (BF.B): 2.07%, Colgate-Palmolive Co (CL): 2.06%, C.R. Bard Inc (BCR): 2.05%, Hormel Foods Corp (HRL): 2.05%, W.W. Grainger Inc (GWW): 2.05%, Clorox Co (CLX): 2.05%, McCormick & Co Inc Non-Voting (MKC): 2.05%
Wed, Apr. 27, 4:38 PM
- C.R. Bard (NYSE:BCR) Q1 results ($M): Total Revenues: 873.5 (+6.6%); Vascular: 239.5 (+3.3%); Urology: 216.7 (+5.4%); Oncology: 241.9 (+7.7%); Surgical Specialties: 151.4 (+11.4%).
- Net Income: 116.2 (-16.9%); Non-GAAP Net Income: 177.0 (+9.5%); EPS: 1.54 (-15.4%); Non-GAAP EPS: 2.34 (+11.4%).
- 2016 Guidance: Revenue growth: 6 - 8%; Non-GAAP EPS: $10.05 - 10.18.
Wed, Apr. 27, 4:23 PM
Tue, Apr. 26, 5:35 PM
- ACGL, AEL, AF, ALGT, AMKR, AMP, ANIK, AR, ASGN, AVB, AVG, BCR, BGC, BKCC, BLKB, CACI, CAKE, CAVM, CBL, CDE, CGI, CLI, CMO, CMPR, CNMD, CNO, CRY, CSGP, CVTI, DGI, DLB, DMRC, DRE, DTLK, DWRE, DXCM, ECHO, EFX, ELY, EQY, ESRT, ESV, EXTR, FB, FIX, FNF, FORM, FORR, FR, FSLR, GG, HOLX, HTCH, HY, IBKC, INFN, IPHS, KEX, KIM, KRA, KRC, KS, LLNW, LOCK, LOGI, LQ, MANT, MAR, MC, MEOH, MMLP, MN, MSTR, MTGE, NE, NEU, NGD, NTGR, NVDQ, OIS, ORLY, OTEX, PEB, PPC, PRXL, PYPL, QDEL, QEP, QGEN, RCII, RGLD, RNG, ROIC, SCI, SFLY, SGI, SIMO, SNDK, SPRT, SSS, STR, TAL, TER, TILE, TS, TTEK, TTMI, TXN, TYL, UHS, UNM, VAR, VRTX, WCN, WIRE, WLL, WRE, WSR, XL, XLNX
Wed, Apr. 20, 4:31 PM
Fri, Mar. 18, 11:38 AM
- Applied Genetic Technologies (AGTC +0.8%) initiated with Buy rating with $25 (85% upside) price target by Janney Capital.
- Nomura's Ed Ridley has been busy in devices. He rates the following companies a Buy: Boston Scientific (BSX +1%) PT: 22 (22% upside); Zimmer Biomet Holdings (ZBH +0.3%) PT: 123 (18% upside); Edwards Lifesciences (EW +0.8%) PT: 101 (19% upside); St. Jude Medical (STJ +0.5%) PT: 64 (19% upside); Stryker (SYK +0.7%) PT: 115 (6% upside); Medtronic (MDT +0.8%) PT: 86 (13% upside). He rates C.R. Bard (BCR +0.7%) Neutral with a PT of $205 (5% upside).
- Tesaro (TSRO +2.6%) initiated with Buy rating and $65 (46% upside) price target by Citigroup.
- CRH Medical (CRHM +0.1%) initiated with Buy rating and $5 (48% upside) price target by Canaccord Genuity.
- Evoke Pharma (EVOK) initiated with an Outperform rating and $16 (258% upside) price target by Northland Securities.
- NanoString Technologies (NSTG -0.2%) initiated with Buy rating and $21 (31% upside) price target by Janney Capital.
- AbbVie (ABBV +0.6%) initiated with Hold rating and $63 (13% upside) price target by Deutsche Bank.
Fri, Jan. 29, 8:43 AM
- C. R. Bard (BCR) Q4 results: Revenues: $870.8M (+0.4%); R&D Expense: $69.4M (-12.4%); SG&A: $279.3M (+8.5%); Net Income: $136.3M (+1.6%); EPS: $1.79 (+4.1%); Non-GAAP EPS: $2.43 (+6.1%).
- FY2015 results: Revenues: $3,416M (+2.8%); R&D Expense: $259.2M (-14.2%); SG&A: $1,012.1M (+3.1%); Net Income: $135.4M (-54.0%); EPS: $1.77 (-52.9%); Non-GAAP EPS: $9.08 (+8.1%).
- 2016 Guidance: $9.90 - 10.05.
Thu, Jan. 28, 4:19 PM
- C. R. Bard (NYSE:BCR): Q4 EPS of $2.43 beats by $0.02.
- Revenue of $870.8M (+0.4% Y/Y) beats by $3.22M.
Wed, Jan. 27, 5:35 PM| Wed, Jan. 27, 5:35 PM | 9 Comments
Mon, Jan. 4, 1:54 PM
- The FDA issues two final orders today to surgical mesh manufacturers and the public with the aim of strengthening the data requirements for the use of the devices to repair pelvic organ prolapse (POP) through the vagina.
- The first order reclassifies the medical devices as Class III, a category for higher-risk products, from Class II, a category for moderate-risk devices.
- The second order requires manufacturers to submit a Premarket Approval (PMA) application to support the safety and effectiveness of surgical mesh for the transvaginal repair of POP. The actions pertain only to mesh devices marketed for this indication. They do not apply to surgical mesh used in other applications such as urinary incontinence or abdominal repair of POP.
- Mesh manufacturers will have 30 months to submit their PMAs for devices already on the market.
- POP occurs when the muscles and tissues of the pelvic floor become stretched or weakened and can no longer support pelvic organs, which drop into the vagina. This causes low back pain, pelvic pressure, painful intercourse, constipation and urinary problems. The transvaginal approach to implanting the device has been a popular method because it reduces recuperation time.
- The FDA issued warnings as early as 2008 concerning complications from the products. Manufacturers are currently working through thousands of product liability claims worth well into the billions of dollars.
- (BSX -2.8%)(JNJ -2.7%)(BCR -2.7%)
- Previously: Lawsuit highlights close ties between doctors and device manufacturers (March 14, 2014)
- Previously: Boston Scientific on the hook for $100M in Delaware transvaginal mesh trial (May 28, 2015)
Dec. 9, 2015, 4:35 PM
- C. R. Bard (NYSE:BCR) declares $0.24/share quarterly dividend, in line with previous.
- Forward yield 0.52%
- Payable Feb. 5; for shareholders of record Jan. 25; ex-div Jan. 21.
Nov. 20, 2015, 7:49 AM
- With the aim of enhancing its presence in the home care market, C.R. Bard (NYSE:BCR) acquires Liberator Medical Holdings (NYSEMKT:LBMH), a direct-to-consumer distributor of Durable Medical Equipment (DME), for $3.35 per share (~$181M).
- Liberator sells general medical supplies including urological catheters, ostomy products, mastectomy fashions, diabetic supplies and a modest amount of Bard's products.
- The transaction, which will add ~$70M to Bard's top line and be slightly accretive to non-GAAP EPS in 2016, should close in Q1. Starting in 2017, the acquisition will add between five and ten cents to non-GAAP cash EPS.
- LBMH is up 25% premarket.
C.R. Bard, Inc. designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. It sells a broad range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.... More
Industry: Medical Instruments & Supplies
Country: United States
Other News & PR